Bladder cancer decisions — 2025

The appeal for service connection for bladder cancer, progressive supra nuclear palsy, diabetes mellitus type II, and gastroesophageal reflux disease (GERD) was dismissed due to the Veteran's death during the pendency of the appeal.

The Board denied a compensable disability rating for the Veteran's residuals of bladder cancer, as the symptoms were attributed to non-service-connected benign prostatic hyperplasia.

The appeal was withdrawn by the appellant, and therefore, it is dismissed.

The Board granted earlier effective dates of August 27, 2021 for bladder cancer and September 23, 2021 for diabetes mellitus type II due to the Veteran's service in Thailand.

The Board denied the veteran's claim for service connection for bladder cancer, finding that the evidence does not support a causal relationship between the condition and his military service.

The Board granted service connection for the cause of the Veteran's death, which was attributed to bladder cancer related to in-service toxic exposure.

The Board remands the claim for a new examination to address the relationship between the Veteran's gallbladder cancer and his conceded exposure to contaminated water at Camp Lejeune.

The Board remands the Veteran's claims for service connection to correct pre-decisional duty to assist errors.

The Board remands the claims for service connection for liver and bladder cancer to obtain additional evidence regarding exposure to ionizing radiation.

The Board granted service connection for left posterior cervical sebaceous cyst excision scar residuals and remanded the claims for other disabilities related to herbicide exposure.

The Board granted an effective date of August 14, 2022, for the award of service connection for gallbladder cancer.

The Board granted an initial rating of 60 percent for the Veteran's service-connected bladder cancer with residual voiding dysfunction, as it required the use of a urinary stoma.

The Board remands the claims for service connection for bladder cancer and incontinence, to include as secondary to bladder cancer, due to a need for a VA examination.

The Board remands the issue of entitlement to service connection for cause of death due to insufficient evidence regarding the Veteran's exposure to herbicide agents and a need for a medical opinion.

The Board granted service connection for bladder cancer, finding that it is at least as likely as not related to the Veteran's in-service exposure to asbestos.

The Veteran was denied a TDIU for the period from August 31, 2010, to January 1, 2015, but granted a TDIU for the period from January 1, 2015, to August 16, 2022 (exclusive of the period from September 18, 2017, to December 31, 2017), and was denied special monthly compensation based on housebound status.

The Board remands the claims for service connection for bilateral hearing loss, bladder cancer, and skin cancer to correct duty to assist errors.

The Board granted service connection for bladder cancer and denied an initial rating in excess of 10 percent for essential tremor, while remanding the other issues for further development.

The Board granted an effective date of September 29, 2023 for the grants of service connection for bladder cancer, skin rash due to chemotherapy, residuals of prostate cancer, hypertension and erectile dysfunction.

The Board granted service connection for the Veteran's cause of death, attributing it to bladder cancer, which was presumed to be related to herbicide exposure during service near the Korean DMZ.